Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million people,

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as cancer, asthma, type 2 diabetes and weight loss - Ozempic, Rybelsus and Wegovy. Austedo and Austedo XR, used to treat Huntington’s disease.

A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable risks.

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.

A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.